Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Drug Profile

Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Alternative Names: c-Stx1; c-Stx1/c-Stx2; c-Stx2; caStx1; caStx1/caStx2; caStx2; Shigamab; Shigamabs®

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sunol Molecular Corporation; Uniformed Services University of the Health Sciences
  • Developer BELLUS Health; Taro Pharmaceuticals Inc
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Escherichia coli infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haemolytic uraemic syndrome
  • Discontinued Shiga-toxigenic Escherichia coli infections

Most Recent Events

  • 16 Mar 2017 Thallion Pharmaceuticals including anti-Shiga toxin monoclonal antibodies acquired by Taro Pharmaceuticals from Bellus Health
  • 12 Nov 2015 BELLUS Health plans a phase II trial for Haemolytic uraemic syndrome (In children)
  • 22 May 2014 Anti-Shiga toxin monoclonal antibodies - BELLUS Health is available for licensing as of 07 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top